Contrasting Endologix (NASDAQ:ELGX) & Hypertension Diagnostics (NASDAQ:HDII)

Endologix (NASDAQ:ELGX) and Hypertension Diagnostics (OTCMKTS:HDII) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Valuation and Earnings

This table compares Endologix and Hypertension Diagnostics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Endologix $143.37 million 0.01 -$64.76 million ($2.19) -0.02
Hypertension Diagnostics $3.68 million 2.93 N/A N/A N/A

Hypertension Diagnostics has lower revenue, but higher earnings than Endologix.

Volatility and Risk

Endologix has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Hypertension Diagnostics has a beta of -2.68, suggesting that its stock price is 368% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Endologix and Hypertension Diagnostics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Endologix 0 2 0 0 2.00
Hypertension Diagnostics 0 0 0 0 N/A

Endologix presently has a consensus target price of $3.00, suggesting a potential upside of 6,733.71%. Given Endologix’s higher probable upside, equities research analysts plainly believe Endologix is more favorable than Hypertension Diagnostics.

Insider & Institutional Ownership

51.6% of Endologix shares are held by institutional investors. Comparatively, 0.0% of Hypertension Diagnostics shares are held by institutional investors. 1.3% of Endologix shares are held by insiders. Comparatively, 40.0% of Hypertension Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Endologix and Hypertension Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Endologix -44.65% -63.96% -13.26%
Hypertension Diagnostics N/A N/A N/A

Summary

Hypertension Diagnostics beats Endologix on 5 of the 9 factors compared between the two stocks.

Endologix Company Profile

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Hypertension Diagnostics Company Profile

Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Minnetonka, Minnesota.

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.